DGCR2-SEC63 Fusion FISH Probe
The DGCR2-SEC63 Fusion FISH Probe is used to confirm a fusion of the DGCR2 and SEC63 genes. The fusion of the DGCR2 and SEC63 genes has been associated with Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| DGCR2-SEC63-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-RERE | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-REOR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-REGO | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-REGR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-OROR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GORE | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GROR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| DGCR2-SEC63-20-AQAQ | 20 (40 μL) | 200 μL |
|
DGCR2 Gene Summary
Deletions of the 22q11.2 have been associated with a wide range of developmental defects (notably DiGeorge syndrome, velocardiofacial syndrome, conotruncal anomaly face syndrome and isolated conotruncal cardiac defects) classified under the acronym CATCH 22. The DGCR2 gene encodes a novel putative adhesion receptor protein, which could play a role in neural crest cells migration, a process which has been proposed to be altered in DiGeorge syndrome. Alternative splicing results in multiple transcript variants.[provided by RefSeq, May 2010]
Gene Name: DiGeorge Syndrome Critical Region Gene 2
Chromosome: CHR22: 19023794 -19109967
Locus: 22q11.21
SEC63 Gene Summary
The Sec61 complex is the central component of the protein translocation apparatus of the endoplasmic reticulum (ER) membrane. The protein encoded by this gene and SEC62 protein are found to be associated with ribosome-free SEC61 complex. It is speculated that Sec61-Sec62-Sec63 may perform post-translational protein translocation into the ER. The Sec61-Sec62-Sec63 complex might also perform the backward transport of ER proteins that are subject to the ubiquitin-proteasome-dependent degradation pathway. The encoded protein is an integral membrane protein located in the rough ER. [provided by RefSeq, Jul 2008]
Gene Name: SEC63 Homolog, Protein Translocation Regulator
Chromosome: CHR6: 108188959 -108279482
Locus: 6q21
Gene Diseases
The DGCR2 SEC63 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Breast Invasive Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|